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Introduction {#sec1}
============

Cutaneous wound healing is a highly coordinated process that includes production of an ordered and dynamic inflammatory response involving multiple growth factors and cytokines ([@bib2]; [@bib25]; [@bib30]; [@bib42]). For most wounds, itching is an unpleasant symptom that arises in the latter part of the healing process. Clinically, in patients with more extensive wounds (e.g., burns), there is more severe and persistent itching ([@bib40]; [@bib39]). Chemically induced itching is evoked by pruritogens activating primary afferent sensory neurons, which innervate the skin and have cell bodies in dorsal root ganglia (DRGs) and trigeminal ganglia. In mice, itch-inducing agents are detected by two nonoverlapping classes of sensory neurons that are thought, in part, to use the ion channel transient receptor potential cation channel subfamily V, member 1 (TRPV1) ([@bib21]; [@bib45]). One of these classes of neurons is marked by the transmitter natriuretic polypeptide B (NPPB) ([@bib35]), which may convey pruritic signals to spinal cord circuits. The second class of neurons is defined by expression of Mas-related G-protein-coupled receptor a3 (Mrgpra3; [@bib18]), which express several itch receptors, including Mrgpra3 and Mrgprc11. Activation of Nppb is sufficient to generate itch behavior ([@bib20]) and is required for interleukin-31 (IL-31)-induced itching ([@bib48]).

The interaction between the nervous system and the immune system has been suggested to be critically involved in normal hemostasis and pathogenic processes ([@bib9]). It has also become increasingly clear that neurological systems regulate immune responses through cell-cell contact ([@bib53]) and/or release of soluble factors ([@bib9]). However, few studies have investigated the reverse direction; i.e., regulation of sensory neurons by the immune system. Specific inflammatory cytokines have been suggested to influence itching in skin ([@bib5]; [@bib22]; [@bib38]), suggesting that inflammation in the skin might play a role in development and pathogenesis of itching. However, the primary factor(s) and the underlying mechanisms of immune-mediated itching during wound healing remain elusive.

Here we utilized an experimental mouse model of wound healing to investigate the effects of immune responses on itching. We showed that IL-31, a prominent cytokine implicated previously in itching ([@bib8]; [@bib13]), was upregulated in skin wound tissue on the fifth day of healing, when itch responses are maximal. We confirmed the itch-promoting effects of IL-31 on the skin and elucidated that IL-31 increased expression of the transduction channel TRPV1 and potentiated calcium influx in DRG neurons. Importantly, we also showed that the major cellular source of IL-31 production is dermal conventional type 2 dendritic cells (cDC2s).

Results {#sec2}
=======

Itch Responses and Changes in IL-31 Expression Follow Similar Time Courses during Wound Repair {#sec2.1}
----------------------------------------------------------------------------------------------

To determine the progression of itch responses during skin wound healing, we monitored pruritus elicited by acute wound healing in humans and mice. For human subjects, we evaluated pruritus in 12 patients (diagnosed with a superficial cyst or benign tumor) using questionnaires for pruritus self-assessment prior to and every other day after surgery, employing a 10-cm visual analog scale (VAS; see [STAR Methods](#sec4){ref-type="sec"} for details). We observed that, in most patients, pruritus reached a peak on the fifth day after surgery ([Figure 1](#fig1){ref-type="fig"} A). Next we used an experimental mouse model of skin wound healing ([@bib3]; [Figure S1](#mmc1){ref-type="supplementary-material"}) and found that, similar to humans, mouse scratching responses ([Video S1](#mmc4){ref-type="supplementary-material"}) were maximal on the fifth day of healing ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Pruritus Elicited by Acute Wound Healing and IL-31 Is Important for Itch during Wound Healing(A) 12 patients with 1- to 3-cm sterile surgical wounds who experienced pruritis were surveyed over 7 days and asked to score the level of itching they felt on each day. One-way ANOVA was used for comparisons. Bars represent means ± SEM. ^∗^p \< 0.05.(B) A mouse wound healing model was established by making 2 equidistant, 1 cm, full-thickness incisional wounds through the dorsal skin and left to heal. The number of scratching bouts per 30 min of observation were measured for 7 days following wounding. Data are from 3 independent experiments (n = 9) and were analyzed with a one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗^p \< 0.05.(C and D) Mouse wound skin at different time points was harvested, followed by RNA-seq of the mRNAs. The Venn diagram (C) shows overlapping of the genes that were significantly changed (p \< 0.01) on the fifth day versus other time points of wound healing and genes related to itching based on published literature. The heatmap (D) shows all the itch-associated genes which changed on the fifth day were compared with any other time points. For RNA-seq, 2 wound tissues from one animal were pooled, and 3 animals were used per time point.(E) The expression of IL-31 in wounds was confirmed by qPCR. Data are from 3 independent duplicated experiments (n = 12) and were analyzed with a one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(F) Itching behaviors of *Il31*^−/−^ mice during wound healing were compared with wild-type mice. Data are pooled from 2 independent experiments (n = 6) and represented as mean ± SEM; two-way ANOVA was used. ^∗∗∗∗^p \< 0.0001.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} for more details.

Video S1. Example of Counting Scratching Bouts in the Mouse Wound Healing Model (Fifth Day), Related to STAR Methods

To investigate whether there are soluble factor(s) present in wounded skin produced by immune cells during wound healing, which might be responsible for itching, we collected tissue and sequenced RNA transcripts several times before and during wound healing. For an unbiased analysis, we examined RNA sequencing (RNA-seq) reads, exploring changes in expression of all genes and focusing on those whose expression changes over the course of the healing process. We hypothesized that the expression of factors contributing to itching would peak at about the same time as itch responses. Next we examined genes, based on published literature ([@bib5]; [@bib37]; [Table S1](#mmc2){ref-type="supplementary-material"}), that might be involved in this process. Using these criteria, we uncovered IL-31 as a candidate for induction of itching after cutaneous incision ([Figures 1](#fig1){ref-type="fig"}C and 1D; [Table S2](#mmc3){ref-type="supplementary-material"}). Confirming our RNA-seq analysis, real-time quantitative polymerase chain reaction (qPCR) and ELISA showed that there was increased expression of IL-31 throughout wound healing that peaked on day 5 after incision ([Figure 1](#fig1){ref-type="fig"}E; [Figure S2](#mmc1){ref-type="supplementary-material"}A).

IL-31 Is Responsible for Itch Responses during Wound Healing {#sec2.2}
------------------------------------------------------------

If IL-31 is responsible for itch responses during wound healing, then we predicted that administration of additional IL-31 should further potentiate these responses. To test this, we injected IL-31 (30 ng/site, intradermally \[i.d.\]) into wounds starting on day 4 (see [STAR Methods](#sec4){ref-type="sec"} for details). In line with our hypothesis, mice treated with additional IL-31 displayed a higher number of scratching bouts compared with untreated animals ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To further investigate the role of IL-31 in itching during wound healing, we used *Il31* ^−/−^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Corroborating a role of IL-31 in wound-induced itching, *Il31* ^−/−^ mice scratched much less than wild-type mice on day 5 of wound healing ([Figure 1](#fig1){ref-type="fig"}F). A similar phenomenon was observed when bone marrow from *Il31* ^−/−^ mice was transferred into irradiated C57BL/6 recipients ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E), indicating that hematopoietic cells, and possibly leukocytes, might be the main source of secreted IL-31.

IL-31 Increases Itch Sensory Neuron Sensitivity {#sec2.3}
-----------------------------------------------

Next, using RT-PCR, we compared the gene expression of molecules associated with signal transduction in DRGs that innervate the wound site between baseline and 5 days after incision. This comparison uncovered that expressions of *Il31ra*, *Trpv1*, and *Nppb* was upregulated during healing in sensory neurons, whereas expression of *Trpa1* did not change significantly ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). Because DRG neurons are a heterogeneous population, *Trpv1-*lineage reporter mice (*Trpv1*-tdTomato mice) were also used to enrich for transcripts present in itch sensory neurons ([@bib36]). qPCR showed that *Il31ra*, *Trpv1*, and *Nppb* ([Figures 2](#fig2){ref-type="fig"} A--2C) were upregulated in sorted DRGs of *Trpv1*-lineage mice (which innervate wounds on day 5 after incision). This result is consistent with IL-31 being involved in induction of increased itch sensitivity in sensory neurons. To further test this hypothesis, we treated mouse DRG sensory neurons *in vitro* with IL-31. We found that IL-31 treatment on its own was sufficient to induce upregulation of *Trpv1*, *Il31ra*, and *Nppb* expression ([Figures S3](#mmc1){ref-type="supplementary-material"}E--S3G). In addition, IL-31 treatment for 24 h could potentiate capsaicin (50 nM)-stimulated calcium influx in cultured DRG neurons ([Figures 2](#fig2){ref-type="fig"}D, [S3](#mmc1){ref-type="supplementary-material"}H, and S3I) and could slightly increase the number of capsaicin-responding neurons in functional assays ([Figure S3](#mmc1){ref-type="supplementary-material"}J). These results suggest that IL-31 may increase the expression of key signal transduction molecules in sensory neurons and that it can sensitize these nerves.Figure 2IL-31 Increases Itch Sensory Neuron Sensitivity(A--C) TRPV1+ cells from DRGs that innervate the fifth day's wounds in *Trpv1-*lineage reporter mice (*Trpv1*-tdTomato mice) were sorted by flow cytometry, and the expression of *Il31ra* (A), *Trpv1* (B), and *Nppb* (C) in these TRPV1+ cells that innervate the fifth day's wounds were compared with TRPV1+ cells that innervate naive skin in normal controls by qPCR. Data were from 2 independent experiments (n = 5), and each sample was pooled from 2 mice. Student's t test was used for comparisons. Bars represent means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01.(D) The calcium transient in capsaicin (50 nM) was observed in DRG neurons treated with IL-31 (10 ng/mL) for 24 h and in untreated neurons. The solid blue and red lines were representative images (mean values) and dash lines were individual traces.(E) Phosphorylation of Stat3 was detected by western blot in DRG neurons treated with IL-31 (10 ng/mL) for 24 h. Data are representative of 3 independent experiments.(F) Scratching bouts of mut-*Stat3* mice were counted after the first IL-31 injection (1 μg/site, i.d.) and compared with wild-type mice. 8 h after the first IL-31 injection, the second IL-31 injection was administered, and the itching behaviors were again observed. Data were from 2 independent experiments (n = 6) and analyzed with a two-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.See also [Figure S3](#mmc1){ref-type="supplementary-material"} for more details.

Because IL-31, via the IL-31ra receptor, may induce changes in gene expression and neural activity through a Jak1-mediated pathway ([@bib58]), we investigated potential additional downstream effectors of IL-31 activation. To do this, we explored, in DRG neurons, which Stat molecules might be regulated by IL-31 treatment. These experiments revealed that IL-31 induces phosphorylation of Stat3 ([Figure 2](#fig2){ref-type="fig"}E). If Stat3 phosphorylation is required for potentiation of neuronal activity, then administration of a specific Stat3 inhibitor should attenuate IL-31-induced increases in calcium responses to capsaicin. Indeed, the Stat3 inhibitor S31-201 blocked IL-31-stimulated increases in calcium influx and the numbers of neurons responding to capsaicin ([Figures S3](#mmc1){ref-type="supplementary-material"}K--S3M). Furthermore, S31-201 inhibited IL-31-induced upregulation of *T* *rpv1* and *Il31ra* expression ([Figures S3](#mmc1){ref-type="supplementary-material"}N and S3O), indicating that these IL-31-mediated effects are Stat3 dependent.

We wondered how IL-31 acts on itch sensory neurons to alter gene expression. To investigate this, we tested the effects of IL-31 on neurons at different time points. We uncovered that Stat3 phosphorylation occurred within 15 min after IL-31 treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}P), but the increase in *Il31ra* and *Trpv1* expression was delayed and started between 1 and 3 h later ([Figures S3](#mmc1){ref-type="supplementary-material"}Q and S3R). Furthermore, when we injected IL-31 (1 μg/site i.d.) into mutant (mut)-*Stat3* mice, the same amount of initial scratching was observed in mut-*Stat3* mice as in wild-type control mice. However, 8 h after the first IL-31 injection, when we gave a second IL-31 dose, scratching was increased markedly in wild-type mice but not in mut-*Stat3* animals ([Figure 2](#fig2){ref-type="fig"}F). In addition, concordant with results from our experiments with a Stat3 inhibitor, *Il31ra* and *Trpv1* gene expression in DRGs that innervate the injected area of skin also showed that IL-31 injection *in vivo* could not upregulate these two genes in the short term (within 1 h) but could increase expression over the long term (8 h) in wild-type mice ([Figures S3](#mmc1){ref-type="supplementary-material"}S and S3T). Notably, this IL-31-induced upregulation did not occur in mut-*Stat3* mice ([Figures S3](#mmc1){ref-type="supplementary-material"}S and S3T). Furthermore, to investigate whether scratching during wound healing is associated with Nppb/Npr1, we injected an Nppb receptor agonist, Npr1 (JS-11, 5 mg/kg intraperitoneally \[i.p.\]) into mice on day 5 of wound healing ([@bib47]). JS-11-treated mice exhibited attenuated scratching 15 min after injection ([Figure S3](#mmc1){ref-type="supplementary-material"}U), indicating that the wound-associated itch is Nppb/Npr1 dependent. Taken together, our results suggest that IL-31 has short-term effects that are Stat3 independent and has longer-term effects on neuronal sensitivity, as evidenced by Stat3-dependent increased *Il31ra* and *Trpv1* expression.

Dendritic Cells Cause Itching during Wound Healing {#sec2.4}
--------------------------------------------------

We next investigated the source of IL-31 in the skin during wound healing. IL-31 has been classified as a T helper 2 (Th2) cytokine ([@bib13]); however, CD3^+^ T cells sorted from wound tissues on day 5 after incision expressed much lower *Il31* than CD3^−^ non-T cells within the CD45^+^ immune cell population ([Figure 3](#fig3){ref-type="fig"} A). Our analysis also revealed that CD45^−^ non-immune cells expressed minimal *Il31* mRNA ([Figure 3](#fig3){ref-type="fig"}A). Confirming these results, the expression of IL-31 detected in wounds from *Rag1* ^−/−^ mice was the same as in control mice ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}A), indicating that T cells or B cells are not a major source of IL-31 in wounds. Again, in line with B and T cells having minimal involvement in wound itching, *Rag1* ^−/−^ mice exhibited similar wound-induced scratch behaviors as wild-type mice ([Figure 3](#fig3){ref-type="fig"}C). When we further fractionated CD3^−^ non-T cells from wound skin, we found that dendritic cells (DCs) had higher expression of *Il31* compared with macrophages, granulocytes, and mast cells ([Figure 3](#fig3){ref-type="fig"}D). Moreover, higher numbers of CD11c^+^ cells were found in day 5 wounds compared with normal skin ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S4](#mmc1){ref-type="supplementary-material"}B).Figure 3Dermal DCs Are a Key Source of IL-31 in Wounds(A) *Il31* gene expression was determined in CD45^−^ cells, CD45^+^CD3^+^ cells, and CD45^+^CD3^−^ cells sorted from fifth-day wounds tissue by qPCR. Data were from 2 independent experiments with 2 samples each time, and each sample was pooled from 4 wounds in 2 mice. Data were analyzed with one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(B) Expression of IL-31 in wounds on the fifth day were tested in *Rag1*^−/−^ mice and wild-type mice by real-time PCR. Data are from 3 independent experiments (n = 6), and two-way ANOVA was used for comparison. Bars represent means± SEM.(C) Scratching behaviors were observed in *Rag1*^−/−^ mice before and on the fifth day of wound healing. Data are from 2 independent experiments (n = 5); Student's t test was used. Bars represent means ± SEM.(D) DCs (CD45^+^CD3^−^CD11c^+^MHC II^+^), macrophages (CD45^+^CD3^−^CD11c^−^CD11b^+^F4/80^+^), granulocytes (CD45^+^CD3^−^CD11c^−^CD11b^+^F4/80^−^), and mast cells (CD45^+^CD3^−^CD11c^−^CD11b^−^FceR1a^+^) were sorted from fifth-day wounds, and the expression of *Il31* was determined by real-time PCR. Data were from 2 independent experiments with 2 samples each time, and each sample was pooled from 4 wounds in 2 mice. Data were analyzed with one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(E and F) The frequency (E) and numbers (F) of CD11c^+^ cells from day 5 wounds was calculated and compared with those from normal skin. Data were from 3 independent experiments (n = 5-6), analyzed with Student's t test for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(G) Itching behaviors during wound healing were observed in diphtheria toxin (DT)-treated (i.p., 500 ng/mouse for the first time and 100 ng/mouse on all subsequent days) zDC^DTR^-to-C57BL/6 bone marrow chimera mice and were compared with DT-treated C57BL/6-to-C57BL/6 bone marrow chimera mice (WT \[wild-type\]). Data were pooled from 6 mice for each condition in two independent experiments and are represented as mean ± SEM. Two-way ANOVA was used for multiple comparisons. ^∗∗∗^p \< 0.001.See also [Figure S4](#mmc1){ref-type="supplementary-material"} for more details.

If DCs are the major source of IL-31 in wounds, then depletion of DCs in the skin should alleviate itching during wound healing. To test this, we made a previously characterized cDC depletion mouse model ([@bib34]) by transferring bone marrow from zDC^DTR^ mice, in which human diphtheria toxin receptor is expressed in cDCs, but not monocytes or other immune cell populations, into irradiated C57BL/6 hosts and injecting diphtheria toxin (DT) to specifically deplete cDCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These mice did not exhibit increased itch behavior during wound healing ([Figure 3](#fig3){ref-type="fig"}G), indicating that cDCs may be the main source of IL-31. Furthermore, *Il31* expression in the wounds of these mice was also lower than in control animals ([Figure S4](#mmc1){ref-type="supplementary-material"}E), but these mice displayed no change in wound closure and healing ([Figure S4](#mmc1){ref-type="supplementary-material"}D). These results establish that DCs are the primary source of IL-31, which causes itching during wound healing.

cDC2s Are a Key Source of IL-31 in Wounds {#sec2.5}
-----------------------------------------

To determine which subset of DCs express IL-31, we next sorted Langerhans cells (LCs), type 1 cDCs (cDC1s), cDC2s, as well as macrophages and found that cDC2s expressed the highest level of *Il31* of all of these types of cells ([Figure 4](#fig4){ref-type="fig"} A). We further used Lang^DTR^ mice, which express the human DT receptor (DTR) downstream of the internal stop codon of the *Langerin* gene, to deplete LCs ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). We also used a well-characterized monocyte/macrophage depletion mouse model by crossing *Lys2* ^Cre^ mice and *Csf1r* ^DTR^ mice ([@bib44]) (hereafter called MM^DTR^ mice). In *Csf1r* ^DTR^ mice, a DTR preceded by a loxP-flanked transcriptional stop element under control of the *Csf1r* promoter, expression of *Cre* recombinase excises the stop element and allows transcription and translation of DTR in cells expressing *Csf1r*, so administering DT to MM^DTR^ mice could deplete macrophages in the skin ([Figures S5](#mmc1){ref-type="supplementary-material"}D--S5F). Itch behaviors during wound healing in these two models were observed. Both models have normal frequencies of cDCs in the skin ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5D) and normal itch behavior on day 5 during wound healing. We also compared *Il31* expression between dermal cDC1s and cDC2 by using CD103 and CD207 as markers to distinguish dermal cDC1s and cDC2s ([@bib23]) and found that dermal cDC2s indeed expressed higher levels of *Il31* than cDC1 ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H). Moreover, *Il31* mRNA expression in cDC2s from day 5 wounds was much higher than in cDC2s from normal skin ([Figure 4](#fig4){ref-type="fig"}B). The proportions ([Figures 4](#fig4){ref-type="fig"}C and 4D) and total numbers of cDC2s ([Figure 4](#fig4){ref-type="fig"}E) were also increased on day 5 after incision compared with naive skin.Figure 4IL-31 in Wounds Was Mostly from Dermal cDC2s(A) Macrophages (CD45^+^CD3^−^CD11c^−^CD64^+^CD11b^+^F4/80^+^), LCs (CD45^+^CD3^−^CD11c^+^CD326^+^), dermal cDC2s (CD45^+^CD3^−^CD11c^+^CD326^−^CD64^−^CD11b^+^MHC II^+^), and dermal cDC1s (CD3^−^CD11c^+^CD326^−^CD64^−^CD11b^−^MHC II^+^) were sorted from fifth-day wounds, and *Il31* expression was determined by real-time PCR. Data were from 2--3 independent experiments with 2 samples each time, and each sample was pooled from 4 wounds in 2 mice. Data were analyzed with one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(B) *Il31* gene expression in dermal cDC2 from fifth-day wounds was compared with cDC2s from normal skin by real-time PCR. Data are from 3 independent experiments with 2 samples each time, and each sample was pooled from 4 wounds in 2 mice. Data were analyzed with Student's t test for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(C--E) Flow cytometer analysis showed that the frequency (C and D) and total numbers of dermal cDC2s (CD45^+^CD11c^+^CD64^−^CD11b^+^MHC II^+^ CD326^−^) (E) were increased in fifth-day wound skin tissues compared with normal skin. In (D) and (E), each circle represents one mouse. Data were from 3 independent experiments (n = 5--6), and Student's t test was used. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.

These results suggest that cDC2s are the likely source of *Il31*, producing increased scratching during wound healing. To further validate this, we examined whether cDC2s are sufficient to elicit wound-like itching. We purified cDC2s from day 5 wounds or normal skin and injected them intradermally in uninjured recipient mice (1.5 × 10^4^ cells per site). cDC2s from wound sites increased scratching in recipient mice 3 h after injection ([Video S2](#mmc5){ref-type="supplementary-material"}) but cDC2s from normal skin did not ([Figure 5](#fig5){ref-type="fig"} A). In addition, consistent with these cDC2s evoking itching through activation of an IL-31 process, expression of *Il31ra* ([Figure 5](#fig5){ref-type="fig"}B), *Trpv1* ([Figure 5](#fig5){ref-type="fig"}C), and *Nppb* ([Figure 5](#fig5){ref-type="fig"}D) was upregulated in DRGs of recipient mice that innervated the skin around cDC2 injection. To probe whether scratching evoked by dermal cDC2 administration elicits itching or nociceptive sensations, we turned to the cheek model ([@bib46]). In this model, scratch responses to intradermal injection of a substance into the face are interpreted to be caused by itching, whereas wipe responses are believed to be triggered by nociception (production of pain). Consistent with cDCs provoking itching, injection of cDC2s from day 5 of wound healing into the cheek caused prominent scratching compared with cDCs from naive mice ([Figure 5](#fig5){ref-type="fig"}E). In contrast, wiping responses were similar for cDCs from naive and day 5 wounds ([Figure 5](#fig5){ref-type="fig"}F). Supporting this conclusion itch responses evoked by day 5 wound cDC2s from *Il31* ^−/−^ mice were similar to the behavior elicited by administration of cDCs from naive skin ([Figure 5](#fig5){ref-type="fig"}G). Taken together, these results suggest that cDC2 is the major source of IL-31 in wounds, which produces itching associated with wound repair.Figure 5Administration of Late Wound Stage Dermal cDC2s Evokes Itch Responses(A--D) Dermal cDC2s sorted from fifth-day wounds or normal skin was injected intradermally to the dorsal area of normal B6 mice at 15,000 per site, and the scratching behaviors were counted 3 h after injection (A). The expression of *Il31ra* (B), *Trpv1* (C), and *Nppb* (D) in DRGs that innervate the back skin around the dermal cDC2-injected area was also determined by real-time PCR. Data were from 2 independent experiments with 3--4 mice each time. Student's t test was used for comparison. Bars represent means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E and F) The numbers of scratching behaviors (E) and wiping behaviors (F) were counted after injection of cDC2s from fifth-day wounds or normal skin to cheeks of mice. Each circle represents one mouse. Data are from 2 independent experiments (n = 8), and Student's t test was used. Bars represent means ± SEM. ^∗∗∗^p \< 0.001.(G) Scratching bouts were counted in recipient mice that were injected with cDC2s from fifth-day wounds of *Il31*^−/−^ mice or WT mice. Data were pooled from 3 independent experiments (n = 9). Each circle represents one mouse. Student's t test was used. Bars represent means ± SEM. ^∗∗^p \< 0.01.See also [Figure S5](#mmc1){ref-type="supplementary-material"} for more information.

Video S2. Example of Counting Scratching Bouts in Mice Receiving a cDC2 Injection, Related to Figure 5

TGF-β Increases IL-31 in Dermal cDC2s {#sec2.6}
-------------------------------------

Because cDC2s in healthy skin contain low amounts of IL-31, we wondered which cues in wounds might be involved in increasing its expression. The cytokines IL-1β, IL-6, IL-17a, transforming growth factor β1 (TGF-β1), and tumor necrosis factor alpha (TNF-α) have been reported to be important participants in coordinating wound repair ([@bib4]; [@bib31]). Therefore, we tested the effects of these cytokines on induction of IL-31 expression in isolated dermal cDC2s *in vitro*. Unexpectedly, only TGF-β1 substantially increased *Il31* expression in cDC2s from normal skin ([Figure 6](#fig6){ref-type="fig"} A). Consistent with TGF-β1 inducing IL-31 in dermal cDC2s, we found that TGF-β1 expression was raised between days 3 and 5 after incision ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Because Smad3 is downstream of canonical TGF-β signaling, we used a TGF-β receptor I (TGF-βRI) inhibitor (SB431542) or a selective Smad3 inhibitor (SIS3) under TGF-β1 culture conditions. Corroborating TGF-βRI and Smad3 as being part of the signal cascade for induction of *Il31* expression, their inhibitors reduced induction of IL-31 transcription ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Further substantiating the contribution of TGF-β in induction of IL-31 expression, the increase in *Il31* expression in response to TGF-β is absent in dermal cDC2s from TGF-βRI global knockout mice (*Tgfbr1* ^f/f^ *Ert2*-Cre) ([Figure 6](#fig6){ref-type="fig"}B) and *Smad3* ^−/−^ mice ([Figure 6](#fig6){ref-type="fig"}C), and *in vitro* TGF-β1 treatment failed to increase *Il31* expression in dermal cDC2s from these knockout mice ([Figures 6](#fig6){ref-type="fig"}B and 6C). To further investigate the role of TGF-βRI in DCs during wound healing, we crossed *Cd11c*-Cre^+^ mice with *Tgfbr1* ^f/f^ mice to conditionally deplete TGFβRI in DCs, whereas other types of cells were untouched. Histological staining showed that conditional depletion of TGF-βRI in DCs did not alter the speed of the wound healing process ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Like the *Tgfbr1* ^f/f^ *Ert2*-Cre mice, TGF-β1 treatment also failed to increase *Il31* expression in dermal cDC2s from *Tgfbr1* ^f/f^ *CD11c-*Cre mice *in vitro* ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Compared with wild-type mice, *Tgfbr1* ^f/f^ *CD11c-*Cre mice exhibited reduced scratching behaviors ([Figure 6](#fig6){ref-type="fig"}D) and a lower *Il31* expression in wounds ([Figure S6](#mmc1){ref-type="supplementary-material"}E) on day 5 after injury. Notably, expression of *Il31ra* ([Figure S6](#mmc1){ref-type="supplementary-material"}F), *Trpv1* ([Figure S6](#mmc1){ref-type="supplementary-material"}G), and *Nppb* ([Figure S6](#mmc1){ref-type="supplementary-material"}H) were also not upregulated in the DRGs that innervated wounds. Furthermore, we generated *Tgfbr1* ^f/f^ *Lyz2*-Cre mice, in which TGF-βRI is eliminated on macrophages but not on DCs. These mice displayed a similar healing process and itching behaviors as wild-type mice ([Figures S6](#mmc1){ref-type="supplementary-material"}J and S6K). Moreover, although the wound healing processes were accelerated ([Figure S6](#mmc1){ref-type="supplementary-material"}L), scratch- and itch-related gene expression in *Smad3* ^−/−^ mice also declined relative to control littermates at all time points ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}M--S6O). Finally, intradermal administration, in recipient animals, of TGF-β1-pretreated dermal cDC2s increased itch behavior (1.5 × 10^4^ cells per site; [Figure 6](#fig6){ref-type="fig"}F). In contrast, TGF-β1-treated dermal cDC2s isolated from *Tgfbr1* ^f/f^ *Ert2*-Cre mice ([Figure 6](#fig6){ref-type="fig"}G) and *Tgfbr1* ^f/f^ *CD11c-*Cre mice ([Figure S6](#mmc1){ref-type="supplementary-material"}I) failed to elicit itch responses. Moreover, even at a low dose of injection (5,000 cells per site), TGF-β1-treated dermal cDC2s could elicit itch responses ([Figure S6](#mmc1){ref-type="supplementary-material"}P) and upregulate *Il31ra* gene expression in DRGs of recipient mice that innervated the skin injected with these cells, although no significant difference in *Trpv1* gene expression could be found ([Figure S6](#mmc1){ref-type="supplementary-material"}Q), whereas TGF-β1-treated dermal cDC2s from *Tgfbr1* ^f/f^ *Ert2*-Cre mice failed to do so ([Figures S6](#mmc1){ref-type="supplementary-material"}R and S6S). Together, these results demonstrate the crucial role of TGF-β signaling in IL-31 production in dermal cDC2s during wound healing.Figure 6TGF-β Increases IL-31 in Dermal cDC2(A) IL-1β (10 ng/mL), IL-6 (50 ng/mL), IL-17a (10 ng/mL), TGF-β1 (2 ng/mL), and TNF-α (10 ng/mL) were used *in vitro* to treat cDC2s sorted from healthy skin individually, and *Il31* expression in dermal cDC2s was determined 6 h after treatment. Data were from 3 independent experiments (n = 6), and each circle represents one culture well. Data were analyzed with one-way ANOVA for comparisons. Bars represent means ± SEM. ^∗∗∗^p \< 0.001.(B and C) The expression of *Il31* in TGF-β1-treated dermal cDC2s from *Tgfbr1*-deficient mice (tamoxifen-treated *Tgfbr1*^f/f^*Ert2*-Cre mice) (B) and Smad3^−/−^ mice (C) were determined and compared with WT dermal cDC2s. Data were from 2 independent experiments (n = 4--8). Each circle represents one culture well, and two-way ANOVA was used for comparisons. Bars represent means ± SEM. ^∗∗∗∗^p \< 0.0001.(D and E) The wound healing model was set up in *Tgfbr1*^f/f^*Cd11c*-Cre (D) and *Smad3*^−/−^ mice (E). Itching behaviors were observed in *Tgfbr1*^f/f^*Cd11c*-Cre mice and *Smad3*^−/−^ mice and compared with WT controls. Data were from 3 independent experiments (n = 6--8) and represented as mean ± SEM. Two-way ANOVA was used for comparisons. ^∗∗∗^p \< 0.001.(F) Dermal cDC2 from normal skin treated with or without TGF-β1 for 24 h were injected (i.d., 15,000 cells per site) to the dorsal area of normal B6 mice, and scratching bouts on the dorsal area of dermal cDC2 recipients were counted 3 h after injection. Data were from 3 independent experiments, each circle represents one mouse (n = 6). Student's t test was used for comparison. Bars represent means ± SEM. ^∗^p \< 0.05.(G) Dermal cDC2 from normal or *Tgfbr1*-deficient mice (tamoxifen-treated *Tgfbr1*^f/f^*Ert2*-Cre mice) were also treated with TGF-β1 for 24 h and injected into the dorsal area of normal B6 mice, and scratch counts were determined in recipients of dermal cDC2s. Data were from 3 independent experiments. Each circle represents one mouse (n = 6). Student's t test was used for comparison. Bars represent means ± SEM. ^∗^p \< 0.05.See also [Figure S6](#mmc1){ref-type="supplementary-material"} for more details.

Discussion {#sec3}
==========

In this study, we investigated the cellular and molecular mechanisms underlying itching during cutaneous wound healing, showing that TGF-β induces expression of IL-31 in dermal cDC2s and that this contributes to generation of scratch behavior through activation of sensory neurons. First we found a close association of the peak of itch responses and cutaneous IL-31 expression. Second, we showed that IL-31 has short-term effects evoking itching, which is Stat3 independent, and long-term effects on increasing the sensitivity of sensory neurons. Third, we established that dermal cDC2s are critical cellular sources of IL-31 during wound repair and that day 5 dermal cDC2s are sufficient to evoke itch responses in naive mice. Finally we demonstrate that IL-31 expression in cDC2s requires Smad-dependent TGF-β signaling. These findings provide the immunological and neurological underpinnings of the widely known sensation of itching that is experienced in the later stages of skin wound healing.

It is thought that many pruritogens evoke itching ([@bib49]; [@bib54]), but the principle underlying the agents responsible for the itching induced during cutaneous repair have not been studied. Here we discovered that the cytokine IL-31, based on our unbiased RNA-seq analysis, qPCR, and protein analysis, was prominently expressed, peaking at approximately the same time when itching was most intense. In mice and humans, type 2 cytokine signaling contributes to itching ([@bib38]), and IL-31 was initially described as a Th2 cytokine mainly related to dermatitis and some respiratory diseases ([@bib6]; [@bib8]; [@bib13]). Supporting this function of IL-31 in itching, anti-IL-31 receptor antibodies have been reported to relieve dermatitis in a mouse model and human patients ([@bib24]; [@bib43]). Therefore, we propose that IL-31 is also a likely agent contributing to pruritus when the skin is recovering from injury, and a slow build-up of IL-31 causes the increasing pruriceptive sensation that builds during wound healing during this process. For this reason, IL-31 might be a good target for treatment of pruritis in more extensive body surface areas, such as with burns.

We wondered why IL-31 might be elevated during wound healing and considered that it might influence immune cell functions at the repair site and, therefore, be important in wound closure or other processes producing an intact barrier. This idea was not borne out because, in *Il31* ^−/−^ mice, we did not find significant changes in wound healing. This still does not answer what IL-31 might be doing, but it means that therapeutic agents neutralizing IL-31 would not impair wound recovery. Future experiments might investigate the reasons for elevated IL-31 during wound repair. In addition, studies have shown that IL-31 has roles in nerve growth ([@bib15]) and neuropeptide release ([@bib33]); it is reasonable that wound itching occurs when nerve fibers are remodeling into the dermis/epidermis.

IL-31 has been reported previously to acutely induce itching via activation of IL-31Ra on TRPV1^+^ sensory neurons, which innervate the skin ([@bib8]), and to also evoke delayed itching ([@bib1]; [@bib19]). Here we showed that, at least in part, IL-31 may increase sensory neuron activity by upregulation of expression of molecules involved in signaling reception (*Il31Ra*), signal transduction (*Trpv1*), and signal transmission (*Nppb*). These increases in expression are long-term effects and are Stat3 dependent. In turn, this suggests that Stat3 might be another potential therapeutic target for use in IL-31-dependent itching.

In the dermis, cDCs are conventional resident DCs and have critical roles in guarding the host against invading pathogens while limiting tissue damage. They are involved in some pathologies, including infectious and parasitic diseases transmitted through the skin ([@bib10]; [@bib55]). cDCs are the most abundant type of DCs in the healthy mouse dermis ([@bib29]; [@bib52]); upon migration to draining lymph nodes, they can trigger Th2 cell differentiation ([@bib27]) and induce production of regulatory T cells ([@bib17]). For these reasons, their numbers are substantially increased at sites of barrier disruption. It has been reported previously that nociceptive sensory neurons, by interacting with dermal cDCs, can regulate the IL-23/IL-17 pathway and control cutaneous immune responses in a model of psoriasis ([@bib41]). Here we focused on the reverse direction and investigated how immune cells affect the peripheral nervous system and behavior. Our results show that elevated amounts of IL-31 in wounds is predominantly generated by dermal cDC2s. Therefore, our results show that there is reciprocal signaling between cutaneous cDC2s and peripheral sensory neurons, highlighting the importance of the interaction between the immune and nervous systems in the skin.

TGF-β signaling is crucial during wound healing; it has a broad spectrum effects on almost every cell type, including keratinocytes, fibroblasts, DCs, and monocytes ([@bib2]). TGF-β1 is important for wound closure by facilitating fibroblast contraction in the collagen matrix ([@bib32]) and development of hypertrophic and keloid scars ([@bib11]) and for inducing and sustaining activation of keloid fibroblasts ([@bib57]). TGF-β1 directs differentiation of monocytes into LCs and is crucial for the cutaneous contingent of migratory DCs ([@bib16]). Moreover, TGF-β may induce tolerogenic DCs, which can skew effector T cell immune response into cells of a predominantly anti-inflammatory Th2-like phenotype or may induce generation of regulatory T cells ([@bib61]; [@bib14]; [@bib56]). In this study, we expand the list of TGF-β functions to wound healing-induced itching by demonstrating that TGF-β signaling increases IL-31 production in dermal cDC2s.

Here we provide evidence of an IL-31-mediated effect on the sensory nervous system and mammalian behavior. By identifying this neuro-immunologic pathway and determining key mechanistic steps involved in this process, we identify potential therapeutic targets for itching that occurs during wound healing and potentially other conditions that disrupt the skin barrier and cause itching.

Limitations of Study {#sec3.1}
--------------------

Although our study shows that IL-31 is responsible for itch responses during wound healing, it remains an exciting question whether there is any other biological function of IL-31 in that period. Future experiments might also investigate the reasons for elevated IL-31 during wound repair; it would be insightful to focus on the roles of IL-31 in nerve growth and neuropeptide release. Our study could be improved by some direct visual evidence of IL-31 expression in the skin, which we were unable to provide because of the coronavirus disease 2019 (COVID-19) pandemic.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse CD45 Alexa Fluor 700 (30-F11)eBioscienceCat\# 56-0451-82; RRID:[AB_891454](nif-antibody:AB_891454){#interref65}Anti-mouse CD3 PerCP-eFluor 710 (17A2)eBioscienceCat\# 46-0032-82; RRID:[AB_1834427](nif-antibody:AB_1834427){#interref70}Anti-mouse CD3 APC-eFluor 780 (17A2)eBioscienceCat\# 47-0032-82; RRID:[AB_1272181](nif-antibody:AB_1272181){#interref75}Anti-mouse CD11c PerCP/Cy5.5 (N418)BioLegendCat\# 117328; RRID:[AB_2129641](nif-antibody:AB_2129641){#interref80}Anti-mouse CD11c FITC (N418)eBioscienceCat\# 11-0114-82; RRID:[AB_464940](nif-antibody:AB_464940){#interref85}Anti-mouse CD11b APC (M1/70)eBioscienceCat\# 17-0112-82; RRID:[AB_469343](nif-antibody:AB_469343){#interref90}Anti-mouse CD11b eFluor 450 (M1/70)eBioscienceCat\# 48-0112-82; RRID:[AB_1582236](nif-antibody:AB_1582236){#interref95}Anti-mouse CD326 APC (G8.8)eBioscienceCat\# 17-5791-82; RRID:[AB_2716944](nif-antibody:AB_2716944){#interref100}Anti-mouse CD326 APC-eFluor 780 (G8.8)eBioscienceCat\# 47-5791-82; RRID:[AB_2573986](nif-antibody:AB_2573986){#interref105}Anti-mouse CD64 PE-Cy7 (X54-5/7.1)BioLegendCat\# 139313; RRID:[AB_2563903](nif-antibody:AB_2563903){#interref110}Anti-mouse CD64 APC (X54-5/7.1)eBioscienceCat\# 17-0641-82; RRID:[AB_2735010](nif-antibody:AB_2735010){#interref115}Anti-mouse CD64 PerCP-eFluor 710 (X54-5/7.1)eBioscienceCat\# 46-0641-82; RRID:[AB_2735016](nif-antibody:AB_2735016){#interref120}Anti-mouse F4/80 APC (BM8)eBioscienceCat\# 17-4801-82: RRID:[AB_2784648](nif-antibody:AB_2784648){#interref125}Anti-mouse F4/80 PE-eFluor 610 (BM8)eBioscienceCat\# 61-4801-82; RRID:[AB_2574612](nif-antibody:AB_2574612){#interref130}Anti-mouse MHC class II (I-A/I-E) PE (M5/114.15.2)eBioscienceCat\# 12-5321-82; RRID:[AB_465928](nif-antibody:AB_465928){#interref135}Anti-mouse MHC class II (I-A/I-E) eFluor 450 (M5/114.15.2)eBioscienceCat\# 48-5321-82; RRID:[AB_1272204](nif-antibody:AB_1272204){#interref140}Anti-mouse CD103 PE (2E7)eBioscienceCat\# 12-1031-82; RRID:[AB_465799](nif-antibody:AB_465799){#interref145}Anti-mouse CD207 PE (eBioL31)eBioscienceCat\# 12-2075-82; RRID:[AB_763452](nif-antibody:AB_763452){#interref150}Anti-mouse CD117 (2B8)eBioscienceCat\# 48-1171-82; RRID:[AB_2574037](nif-antibody:AB_2574037){#interref155}Anti-mouse FceR1 alpha PerCP-eFluor 710 (MAR-1)eBioscienceCat\# 46-5898-82; RRID:[AB_2573801](nif-antibody:AB_2573801){#interref160}Anti-mouse Stat1Cell SignalingCat\# 9172; RRID:[AB_2198300](nif-antibody:AB_2198300){#interref165}Anti-mouse pStat1Cell SignalingCat\# 9171S; RRID:[AB_331591](nif-antibody:AB_331591){#interref170}Anti-mouse Stat3Cell SignalingCat\# 9139; RRID:[AB_331757](nif-antibody:AB_331757){#interref175}Anti-mouse Stat3Cell SignalingCat\# 4904S; RRID:[AB_331269](nif-antibody:AB_331269){#interref180}Anti-mouse pStat3Cell SignalingCat\# 9131S; RRID:[AB_331586](nif-antibody:AB_331586){#interref185}Anti-mouse pStat3Cell SignalingCat\# 9145S; RRID:[AB_2491009](nif-antibody:AB_2491009){#interref190}Anti-mouse Stat5Cell SignalingCat\# 9363; RRID:[AB_2196923](nif-antibody:AB_2196923){#interref195}Anti-mouse pStat5Cell SignalingCat\# 9351S; RRID:[AB_2315225](nif-antibody:AB_2315225){#interref200}Anti-mouse GapdhCell SignalingCat\# 5014S; RRID:[AB_10693448](nif-antibody:AB_10693448){#interref205}Anti-mouse IL-31ABcamCat\# ab102750; RRID:[AB_10710722](nif-antibody:AB_10710722){#interref210}TGF-β1 Elisa kitPromegaCat\# G7591; RRID:[AB_2858628](nif-antibody:AB_2858628){#interref215}IL-31 Elisa kiteBioscienceCat\# BMS6030; RRID:[AB_2575653](nif-antibody:AB_2575653){#interref220}**Chemicals, Peptides, and Recombinant Proteins**Recombinant mouse IL-1βR&D SystemCat\# 401-MLRecombinant mouse IL-6R&D SystemCat\# 206-ILRecombinant mouse IL-17aR&D SystemCat\# 421-MLRecombinant mouse IL-31R&D SystemCat\# 3028-MLRecombinant human TGF- β1R&D SystemCat\# 240-BRecombinant mouse TNF-αR&D SystemCat\# 410-MTSB431542SelleckchemCat\# S1067S31-201SigmaCat\# SML0330SIS3SigmaCat\# S0447CapsaicinSigmaCat\# M2028poly-D-lysineSigmaCat\# A-003-MTamoxifenSigmaCat\# T5648Liberase DHSigmaCat\# LIBDH-ROPapainWorthingtonCat\# LS003127Collagenase type IIWorthingtonCat\# LS004177Dispase type IIWorthingtonCat\# LS02104Fluo-4Thermo Fisher ScientificCat\# F14201Pluronic F-127Thermo Fisher ScientificCat\# P3000MPJS-11[@bib47]N/A**Critical Commercial Assays**RNeasy Mini KitQIAGENCat\# 74106RNeasy Micro KitQIAGENCat\# 74004High-Capacity cDNA Reverse Transcription KitApplied BiosystemsCat\# 4368814TaqMan Gene Expression Master MixApplied BiosystemsCat\# 4369016TaqMan PreAmp Master Mix KitApplied BiosystemsCat\# 4488593**Deposited Data**Murine cutaneous wounds tissue RNA sequence dataThis PaperGEO accession [GSE128193](ncbi-geo:GSE128193){#intref0010}<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128193>**Biological information**Pruritus self-assessments of patients who were scheduled for minor skin superficial surgery were recorded before and every other day after surgery for 7 days, no human tissue sample was taken for this studyThis PaperN/A**Experimental Models: Organisms/Strains**Mouse: C57BL/6The Jackson LaboratoryCat\# 000664Mouse: *Il31*^−/−^[@bib51]N/AMouse: *Trpv1*-creThe Jackson LaboratoryCat\# 017769Mouse: Rosa26^tdTomato^The Jackson LaboratoryCat\# 007914Mouse: *Trpv1*-tdTomatoThis paperN/AMouse: mut-*Stat3*The Jackson LaboratoryCat\# 027952Mouse: zDC^DTR^The Jackson LaboratoryCat\# 019506Mouse: *Rag1*^−/−^The Jackson LaboratoryCat\# 002216Mouse: *Lang*^DTR^The Jackson LaboratoryCat\# 016940Mouse: *Csf1r*^DTR^The Jackson LaboratoryCat\# 024046Mouse: *Csf1r*^DTR^ Lyz2-cre[@bib44]N/AMouse: *Tgfbr1*^f/f^ Ert2-cre[@bib59]N/AMouse: *Smad3*^*−/−*^[@bib60]N/AMouse: *Tgfbr1*^f/f^ Cd11c-creThis paperN/AMouse: *Tgfbr1*^f/f^ Lyz2-creThis paperN/A**Oligonucleotides**TaqMan *Hprt* primer, Mm00446968_m1Applied BiosystemsN/ATaqMan *Gapdh* primer, Mm99999915_g1Applied BiosystemsN/ATaqMan *Il31* primer, Mm01194496_m1Applied BiosystemsN/ATaqMan *Il31ra* primer, Mm01304494_m1Applied BiosystemsN/ATaqMan *Trpa1* primer, Mm01227437_m1Applied BiosystemsN/ATaqMan *Trpv1* primer, Mm01246302_m1Applied BiosystemsN/ATaqMan *Nppb* primer, Mm01255770_g1Applied BiosystemsN/A**Software and Algorithms**FlowJo 9 softwareFlowJo<https://www.flowjo.com>; RRID:[SCR_008520](rridsoftware:SCR_008520){#intref0025}GraphPad Prism 7 softwareGraphPad Software<https://www.graphpad.com>; RRID:[SCR_002798](rridsoftware:SCR_002798){#intref0035}RStudioRStudio<https://rstudio.com/>; RRID:[SCR_000432](rridsoftware:SCR_000432){#intref0045}**Other**BD LSRFortessaBD BiosciencesN/ABD FACSAria cell sorterBD BiosciencesN/A

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, WanJun Chen (<wchen@mail.nih.gov>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents

### Data and Code Availability {#sec4.2.3}

Murine cutaneous wounds tissue RNA sequence data in this paper were deposited in GEO accession (GSE128193; <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128193>)

Experimental Models and Subject Details {#sec4.3}
---------------------------------------

### Human data of pruritus questionnaires {#sec4.3.1}

The questionnaires for pruritus self-assessment was approved by the Institutional Ethics Committee of Beijing Stomatological Hospital affiliated to Capital Medical University; informed consent was obtained from all participants. Pruritus self-assessments were recorded for subjects who were scheduled for minor skin superficial surgery (please see [Method Details](#sec4.4){ref-type="sec"} for details). 12 subjects were enrolled finally (3 women and 9 men, mean age ± SD: 53.3 ± 12.6 years). Pruritus intensity was assessed using a 10-cm visual analog scale (VAS). Subjects were asked to evaluate and record the pruritus intensity before and every other day after surgery within 7 days. No human tissue sample was taken for this study.

### Mice {#sec4.3.2}

C57BL/6, *Rag1* ^−/−^ mice, *Trpv1*-Cre mice, Rosa26^tdTomato^ mice, mut-*Stat3* mice ([@bib50]), zDC^DTR^ mice ([@bib34]), *Csf1r* ^DTR^ mice, *Lang* ^DTR^ mice ([@bib26]) were obtained from The Jackson Laboratory. *Il31* ^−/−^ mice ([@bib51]) were obtained from Dr. Nakae's Lab. *Tgfbr1* ^f/f^ *Ert2*-Cre, *Smad3* ^−/−^ (on a C57BL/6 background) were previously described and bred in our facility under specific pathogen-free conditions. *Trpv1* ^tdTomato^ mice were generated in-house by crossing *Trpv1-*Cre mice with Rosa26^tdTomato^ mice. *Csf1r* ^DTR^ *Lys2-*Cre mice (MM^DTR^ mice) ([@bib44]) were generated in-house by crossing *Lys2-*Cre mice with *Csf1r* ^DTR^ mice. *Tgfbr1* ^f/f^ *Cd11c*-Cre^+^ mice were generated in-house by crossing *Cd11c*-Cre mice with *Tgfbr1* ^f/f^ mice. *Tgfbr1* ^f/f^ *Lyz2*-Cre^+^ were generated in-house by crossing *Lyz2*-Cre mice with *Tgfbr1* ^f/f^ mice. *Tgfbr1* ^f/f^ *Ert2*-Cre mice were treated with tamoxifen (1 μg/mouse) per day for 5 days to delete TβRI. All mice used for experiments were aged 6-12 weeks, both male and female. All animal studies were performed according to National Institutes of Health (NIH) guidelines for use and care of live animals and approved by the Animal Care and Use Committees of National Institute of Dental and Craniofacial Research (NIDCR).

Method Details {#sec4.4}
--------------

### Enroll and exclusion criteria for human pruritus questionnaires {#sec4.4.1}

All subjects must fulfill all the following items: (1) a superficial surgery is necessary for the subject diagnosed with a superficial cyst or benign tumor; (2) the expected wound will be 1 cm to 3 cm long; (3) the subject has no active systemic disease for 1 year and have a negative history of skin diseases; (4) the surgical area has no inflammation within the recent 6 months and have no sign of infection; (5) subject must be informed of the investigational nature of this study and given written informed consent. Exclusion criteria: (1) Active, uncontrolled infections in surgical area or systemically; (2) pathology report shows as a malignant tumor or Kimura's disease; (3) failed to follow up entirely.

### Bone marrow chimeras and diphtheria toxin injection {#sec4.4.2}

C57BL/6 hosts were irradiated with 12Gy split into 3 doses and reconstituted by tail vein injection of 5 × 10^6^ bone marrow cells from WT, *Il31* ^−/−^ or zDC^DTR^ donors. Mice were allowed to reconstitute for 6 weeks prior to use. Diphtheria toxin (DT) was purchased from Sigma-Aldrich. zDC^DTR^ bone marrow chimeras were injected *i.p.* with 20 ng DT per gram of body weight (500 ng/mouse) on the first day of DC depletion and with 4 ng DT per gram body weight (100 ng/mouse) on all subsequent days. C57BL/6, Lang^DTR^, and MM^DTR^ mice received 4 ng DT per gram body weight (100 ng/mouse) at any time. Since we found that macrophage depletion at the beginning of incising would delay the wound healing or even fatal for mice, DT was injected (*i.p.*, 100ng/mouse) to MM^DTR^ mice on the 3^rd^ of wound healing and every day thereafter.

### Murine wound healing {#sec4.4.3}

Mice were anesthetized, dorsum shaved, cleaned with alcohol, and 2 equidistant 1cm full-thickness incisional wounds were made through the skin and left to heal. Wounds tissue (0.5 cm around incision) and dorsal root ganglion (DRG) that innervate the wound were harvested at indicated days and bisected for histology, snap-frozen in for RNA analysis/protein extraction, or DMEM contained 10% fetal bovine serum on ice for flow cytometry. Wound sizes were measured and wound healing rates were evaluated by the formula $\left( {{\left( {\pi/4} \right) \times length0 \times width0 - \left( {\pi/4} \right) \times lengthf \times widthf}/{\left( {dayf - day0} \right) \times \left( {\pi/4} \right) \times length0 \times width0}} \right) \times 100$ ([@bib12]; [@bib28]) and HE staining ([@bib7]).

### IL-31 intradermal injection {#sec4.4.4}

For wound healing model, we intradermally injected IL-31 30 ng/site (by this dose IL-31 could not induce itch in naive mice 8 hours later; [@bib1]) into wounds every 12 hours for 3 times from the fourth day after wounds were cut, and the behavior recordings were taken 8 hours after the last injection. For mut-*Stat3* mice or wild-type control mice, we injected IL-31 1 μg/site on the dorsal area intradermally, and observe the itching behaviors 1 hour later; 8 hours after the 1^st^ injection, another IL-31 injection (1 μg/site, *i.d.*) on the same spot, itching behaviors were recorded again 1 hour after the 2^nd^ injection.

### Pruriceptive behavior measurement {#sec4.4.5}

To measure the pruriceptive behaviors, mice were placed in clear plastic enclosures with an optical cannula, which could rotate to allow free movement of the mouse. Itch behavioral responses were videotaped during the experiment. The behavior experiments and analysis were done blinded. Scratch (by the hind leg) bouts around the wounds or dendritic cells injected area were counted for 30 or 60 minutes.

### RNA-seq analysis {#sec4.4.6}

Two wounds tissue from one animal were pooled, three animals were used per time point. The skin was cleaned of muscle and fat tissue; total RNA was extracted using the RNeasy mini kits (QIAGEN), purified using Direct-zol RNA MiniPrep kit (Zymo Research). Next-generation libraries were prepared using the VAHTS TM mRNA-seq V2 Library Prep Kit for Illumina (Vazyme, \#NR601). RNA-seq libraries were run on an Illumina HiSeq X-Ten next-generation sequencer. Analysis of RNA-seq data was done using the DESeq package in R.

### Cell culture of dorsal root ganglion neurons {#sec4.4.7}

Dorsal root ganglion (DRG) neurons were primarily cultured, as described previously. Briefly, thoracic and lumbar DRGs were dissected and collected from adult mice and transferred into HBSS without Ca^2+^/Mg^2+^ on ice. F12 with 10% FCS and 100 U/ml penicillin/streptomycin was used as a culture medium. Ganglia were incubated with 1.5 mL papain (40 U/ml, Worthington) for 10 min at 37°C and then with 3 mL collagenase type II (4 mg/ml, Worthington)/ dispase type II (4.67 mg/ml, Worthington) combined solution for 10 min at 37°C. Dissociated cells were plated on poly-D-lysine-treated small coverslips and incubated for 2 to 3 days at 37°C in 95% air/5% CO^2^.

### Calcium image {#sec4.4.8}

DRG neurons were stained by 5 μM Fluo-4 (Thermo Fisher Scientific) with 0.02% F-127 (Thermo Fisher Scientific) in HBSS^+/+^ RP free buffer at 37°C for 30 mins. Then coverslips with cells were washed, moved to a custom-built chamber, and incubated with image medium (pH 7.4; 140 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 2 mM MgCl~2~, 10 mM HEPES, 10 mM Glucose). Calcium imaging experiments were performed under a Nikon confocal microscope with 488 nm excitation wavelength. Neurons were stimulated by Capsaicin (50 nM, Sigma) 10 s after the time lapse started. Images were analyzed offline with an NIH ImageJ software, data were normalized by using the initial image as basal fluorescence, and presented as the relative change in fluorescence (ΔF/F~0~), where F~0~ is basal fluorescence and ΔF = F − F~0~

### Flow cytometry {#sec4.4.9}

The skin was cleaned of fat tissue and cut into small pieces, incubated in Liberase DH (0.5 mg/ml, Sigma) for 90 min before finally shredding through 70-μm cell strainers (BD PharMingen). After isolation, cell suspensions were washed by 0.5% BSA in PBS and passed through 40 μm cell strainers (BD PharMingen), and cell populations were characterized by flow cytometry. Stained cells were analyzed on LSRFortessa (BD Biosciences) or separated by FACSAria cell sorter (BD Biosciences). Data were analyzed with FlowJo software,

### Dermal conventional type 2 dendritic cells culture and injection {#sec4.4.10}

Dermal conventional type 2 dendritic cells (cDC2) were sorted by FACS Aria cell sorter (Zombie^-^CD45^+^CD3^-^CD64^-^CD11c^+^CD326^-^CD11b^+^MHC II^+^) and cultured with complete medium (RPMI 1640 supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, 2-mercaptoethanol) contained GM-CSF (20 ng/ml, Peprotech). For cDC2 injection, mice were dorsum shaved 1 day before injection, cDC2 were washed and suspended in HBSS^+/+^ RP free buffer and injected intradermally (5000 cells or 15000 cells in 20 μL per site), pruriceptive behaviors were observed before and after injections.

### Real-time PCR {#sec4.4.11}

Total RNA was derived from cultured cells with RNeasy Mini kits (QIAGEN) or RNeasy Micro kits (QIAGEN), cDNA was synthesized using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). For sorted cells, a TaqMan PreAmp Master Mix Kit (Applied Biosystems) was used before quantitative real-time PCR. Quantitative real-time PCR was performed according to the protocol of TaqMan gene expression assay kits (Applied Biosystems). Results from leukocytes were normalized to the expression of *Hprt* mRNA, results from tissue were normalized to the expression of *Gapdh* mRNA.

### Antibodies and reagents {#sec4.4.12}

The following fluorochrome-conjugated antibodies were used for flow cytometry surface staining: anti-mouse CD45 (30-F11, eBioscience), anti-mouse CD3 (17A3, eBioscience), anti-mouse CD11c (N418, eBioscience), anti-mouse CD11b (M1/70, eBioscience), anti-mouse MHC class II (I-A/I-E) (M5/114.15.2, eBioscience), anti-mouse F4/80 (BM8, eBioscience), anti-mouse CD64 (X54-5/7.1, eBioscience), anti-mouse CD117 (2B8, eBioscience), anti-mouse Fc epsilon Receptor 1 alpha (MAR-1, eBioscience), anti-mouse CD207 (eBioL31, eBioscience), anti-mouse CD326 (G8.8, eBioscience), anti-mouse CD103 (2E7, eBioscience). Dead cells were excluded from analysis using Zombie Yellow Fixable Viability Kit (Biolegend). Recombined proteins and chemicals: IL-1β (401-ML, R&D System), IL-6 (206-IL, R&D System), IL-17a (421-ML, R&D System), IL-31 (3028-ML, R&D System), TGF-β1 (240-B, R&D System), TNF-α (410-MT, R&D System), SB431542 (ALK5 inhibitor, Selleckchem), S3I-201 (Stat3 inhibitor, Selleckchem), and SIS3 (Smad3 inhibitor, Sigma) were used in cell culturing for different conditions. Anti-mouse Stat1 (\#9172, Cell Signaling), anti-mouse pStat1 (\#9171S, Cell Signaling), anti-mouse Stat3 (\#9139, Cell Signaling), anti-mouse pStat3 (\#9131S, Cell Signaling), anti-mouse Stat5 (\#9363, Cell Signaling), anti-mouse pStat5 (\#9351S, Cell Signaling), anti-mouse Gapdh (\#5014S, Cell Signaling), anti-mouse IL-31 (ab102750, ABcam) were used for western blot. TGFβ1 Elisa kit (G7591, Promega) and IL-31 Elisa kit (BMS6030, eBioscience) were used for TGFβ1 or IL-31 protein determination.

### Statistical analysis {#sec4.4.13}

Statistical analysis was performed using either unpaired two-tailed Student's t tests or one-way ANOVA in GraphPad Prism.
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